LAG3 and cancer: The recent approval of Opdualag, a novel immune checkpoint inhibitor fixed-dose treatment combination of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) developed by Bristol Myers Squibb for the treatment of first-line unresectable melanoma or melanoma that has spread (advanced melanoma) is a significant large milestone in the clinical landscape of cancer treatment.